Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
We tested 21, including those from Arctic Fox, L'Oréal Paris, Madison Reed, Manic Panic, and Naturtint. Plus, advice on ...
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 ...
Researchers at UC Davis found in a mouse study that chemicals commonly found in disinfectant sprays may be more harmful than once thought. (Getty) Breathing in common disinfectant chemicals known as ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...
Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...
Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...
Bathrooms are a high-traffic area in every home—and staying on top of germs and bacteria calls for a regular cleaning routine with frequent disinfecting. For a multi-use product that can tackle ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...
Short-acting bronchodilators offer quick relief of respiratory symptoms, with effects lasting from 30 minutes to several hours. They are often used as a rescue medication. Long-acting bronchodilators ...
Managing mucus from COPD involves strategies that can help loosen mucus and clear it from your airway, such as staying hydrated, exercising, and quitting smoking. Specific breathing techniques, ...